Compare Summit Therapeutics Inc (SMMT) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Stanley Black & Decker, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Stanley Black & Decker, Inc. trades at $88.68 (market cap $13.47B). The key difference: Summit Therapeutics Inc and Stanley Black & Decker, Inc. are close in size by market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| SMMT | SWK | |
|---|---|---|
Market Cap | $13.71B | $13.47B |
Volume | 6,173,057 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $26.38 | $104.00 |
52-Week Low | $12.43 | $62.12 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $13.04B | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Stanley Black & Decker (SWK) trades at $88.49, up 0.2% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89. Recent news highlights new product launches and dividend consistency as a Dividend King.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness. The consensus price target of $93.00 suggests 5% upside potential, but investors face execution risks amid competitive pressures and ongoing operational challenges. The stock's dividend history provides income stability while awaiting fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
